Description
CGP52411 (DAPH) is a highly selective, orally active, and ATP-competitive EGFR inhibitor (IC50: 0.3uM). It blocks the toxic influx of Ca2+ ions into neuronal cells and dramatically inhibits and reverses the formation of beta-amyloid (Abeta42) fibril aggregates